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Abstract
Background: Leptospirosis, a zoonosis caused by Leptospira spp., is recognized as an emergent infectious disease.
Due to the lack of adequate diagnostic tools, vaccines are an attractive intervention strategy. Recombinant proteins
produced in Escherichia coli have demonstrated promising results, albeit with variable efficacy. Pichia pastoris is an
alternative host with several advantages for the production of recombinant proteins.
Results: The vaccine candidates LigANI and LipL32 were cloned and expressed in P. pastoris as secreted proteins.
Large-scale expression resulted in a yield of 276 mg/L for LigANI and 285 mg/L for LipL32. The recombinant
proteins were glycosylated and were recognized by antibodies present in the sera of patients with severe
leptospirosis.
Conclusions: The expression of LigANI and LipL32 in P. pastoris resulted in a significant increase in yield compared
to expression in E. coli. In addition, the proteins were secreted, allowing for easy purification, and retained the
antigenic characteristics of the native proteins, demonstrating their potential application as subunit vaccine
candidates.
Background
Leptospira interrogans sensu lato is the causative agent
of Leptospirosis, one of the most widespread zoonotic
diseases in the world [1-3]. In Brazil alone there are
over 10,000 cases of leptospirosis reported annually dur-
ing the epidemics that affect the poor communities in
the major urban centres of Brazil [4]. Mortality ranges
from 10-15% in cases of the traditional Weil’s disease
and can be over 70% in cases of severe pulmonary hae-
morrhage syndrome (SPHS) and, even with aggressive
intervention strategies, mortality remains high [5-7].
Due to the lack of adequate tools leptospirosis is under-
diagnosed, therefore vaccination remains a viable alter-
native for the management of this disease. Several
groups, including our own, have demonstrated the use
of subunit vaccines against leptospirosis, albeit with
varying degrees of efficacy [8-10], in particular the use
of the Leptospiral immunoglobulin-like (Lig) proteins,
LigA and LigB [11-14], and the immunodominant lipo-
protein, LipL32 [15-18].
Escherichia coli has been used extensively as a host for
heterologous protein expression, but potential limita-
tions include the yield, folding and post-translational
modifications of the recombinant protein. An alternative
host to E. coli is the methylotrophic yeast, Pichia pas-
toris. This yeast strain has emerged as a powerful and
inexpensive expression system for the heterologous pro-
duction of recombinant proteins with the following
characteristics: (i) techniques for genetic modifications
are available; (ii) proteins may be secreted; (iii) post-
translational modification and (iv) high yield, reviewed
in [19-21].
We previously expressed the Lig polypeptides, LigANI,
LigBNI and LigBrep, in several E. coli-based expression
systems. To date the recombinant proteins were insolu-
ble, required extensive dialysis during purification and
the yield was poor [13]. In this work we describe the
use of the methylotrophic yeast P. pastoris for the
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cloning, expression, purification and antigenic character-
ization of the leptospiral vaccine candidates LigANI and
LipL32.
Results
Plasmid construction and sequence analysis
The DNA sequences that encode for the LigA polypep-
tide, LigANI, (1800 bp) and LipL32 (766 bp) were
amplified by PCR and cloned into the P. pastoris expres-
sion vector pPICZaB. Of the 150 P. pastoris colonies
screened for expression of each recombinant protein, 30
colonies were strongly recognised by a monoclonal anti-
body (Mab) specific to the 6×His tag at the C-terminus
of the recombinant proteins. Colony PCR was used to
confirm the presence of the insert in the expression vec-
tor and clones exhibiting the highest expression levels
were selected for further expression studies, Figure 1.
Expression of LigANI and LipL32 in P. pastoris
The coding sequences for the recombinant proteins
LigANI (rLigANI) and LipL32 (rLipL32) cloned in pPIC-
ZaB were under the control of the AOX1 promoter. In
addition, pPICZaB contains the a-factor signal sequence
from S. cerevisiae, allowing secretion of the recombinant
protein. The concentration of rLigANI and rLipL32 in
the culture supernatant was found to increase with time,
Figure 2A, and is related with a decrease in the intracel-
lular concentration of rLigANI, Figure 2B and 2C. In
contrast, while the secretion of rLipL32 increased, so
did the intracellular concentration, Figure 2D and 2E.
Recombinant proteins of the expected size were
observed, rLigANI (61 kDa) and rLipL32 (32 kDa), yet
there was evidence of larger proteins, suggesting that
the recombinant proteins had been glycosylated by P.
pastoris. Following 196 h induction at 28°C, the
concentration of secreted protein reached 0.93 g/L and
1.2 g/L for rLigANI and rLipL32, respectively. Large-
scale (2 L cultures) expression of rLigANI and rLipL32
resulted in yields of 276 mg/L and 285 mg/L,
respectively.
Recombinant protein purification and concentration
The supernatant containing the secreted rLigANI and
rLipL32 was collected and purified/concentrated using
three alternative methods. In the first method, the pro-
teins were purified by ammonium sulphate precipitation.
The optimal salt concentration for rLigANI was 70-80%,
while the precipitation of rLipL32 was similar under all
concentrations tested. The recombinant proteins were
dialyzed to remove the ammonium sulphate and then
analysed by Western blotting, Figure 3A, B. Once again,
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Figure 1 Screening for P. pastoris recombinant clones
expressing rLigANI and rLipL32. Colony blot analysis of
transformed P. pastoris strain KM71 H with anti-6×His Mab. The tgD
recombinant protein expressed in P. pastoris KM71 H was the
positive control (+) and untransformed P. pastoris KM71 H was the
negative control (-). Spots 1-7 are representative rLigANI colonies
and 8-12 are representative rLipL32 colonies. Arrows indicate the
colonies that were selected for large-scale expression studies.
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Figure 2 Expression of rLigANI and rLipL32 proteins in
P. pastoris. Time courses for the expression of secreted rLigANI and
rLipL32 by P. pastoris induced for up to 192 hours (8 days), (A) as
determined by protein concentration (mg/mL). Western blot
analysis of the intracellular (pellet) and secreted (supernatant)
expression of rLigANI (B and C, respectively) and rLipL32 (D and E,
respectively), using polyclonal anti-LigANI sera or anti-LipL32 Mab.
Samples (cells and supernatant) were collected at the various hourly
time points indicated. KM - negative control: untransformed
P. pastoris KM71 H culture.
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there was evidence of post-translation modification of
the recombinant proteins. The yield for both rLigANI
and rLipL32 was similar, approximately 70 mg/L, corre-
sponding to 24.5 and 27.6% of total protein, respectively.
In the second method, the supernatant was concentrated
by ultrafiltration which reduced the starting volume by
97%. The yield for rLigANI was 183 mg/L (66.3% total
protein) compared to 106 mg/L (37.3% total protein) for
rLipL32. The samples were observed by 12% SDS-PAGE
and compared to recombinant proteins expressed and
purified from E. coli (Figure 3C). In the third method,
the secreted proteins were concentrated by lyophilisa-
tion. There was a 10-fold reduction in the initial sample
volume and the yield was 239 mg/L rLigANI and 224
mg/L rLipL32, equivalent to 86.7 and 70.7% total pro-
tein, respectively.
Deglycosylation of LigANI and LipL32
In an analysis, using Vector NTI Advance 10.0 (Invitro-
gen) software, of the recombinant protein amino acid
sequences, LigANI was found to have seven potential
N-glycosylation sites, compared to one for LipL32.
N-Glycosidase F (PNGase F) removes oligomannose,
hybrid, and complex N-glycans attached to asparagine,
while Endoglycosidase H (Endo H) releases oligoman-
nose and hybrid N-glycans, but not complex N-glycans,
and were used to deglycosylate the recombinant pro-
teins. Following deglycosylation, the larger molecular
weight species were no longer evident and the size of
the rLigANI and rLipL32 corresponded to the equiva-
lent protein produced in E. coli, Figure 4. There did not
appear to be any difference in action between the two
enzymes used.
Antigenicity of the recombinant LigANI and LipL32
proteins
The antigenicity of the purified proteins was evaluated
by Western blotting with sera from leptospirosis
patients and with rabbit anti-Leptospira hyperimmune
sera. The recombinant proteins LigANI and LipL32 pro-
duced in E. coli were included as positive controls. Both
glycosylated and deglycosylated (Endo H and PNGase F
treated) rLigANI were recognised by the human and
rabbit immune sera, Figure 5A, C and 5D, as were the
glycosylated and deglycosylated forms of rLipL32, Figure
5B, C and 5D.
Discussion
Previous studies have demonstrated the use of the Lig
proteins and LipL32 in a range of formats, including
recombinant proteins [11-14], DNA vaccines [17,22],
microspheres and liposomes [23,24], fused to a cholera
toxin subunit [25] or expressed in M. bovis bacille
Calmette-Guérin [16]. However, vaccine efficacy in the
animal models has been highly variable for these and
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Figure 3 Purification of rLigANI and rLipL32 expressed in P.
pastoris. Recombinant proteins purified by precipitation with
ammonium sulphate or by ultrafiltration. Ammonium sulphate
precipitated proteins were detected by Western blotting with (A)
polyclonal anti-LigANI sera or (B) an anti-LipL32 Mab. The effect of
the various concentrations of ammonium sulphate (expressed as
percentage values) on the precipitation of the recombinant proteins
is displayed. (C) Affinity chromatography purified recombinant
LigANI (61 kDa) and LipL32 (32 kDa) produced in E. coli compared
to purification by ultrafiltration of rLigANI and rLipL32 secreted by P.
pastoris. An equal volume (10 μL) of both proteins was loaded on
the gel.
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Figure 4 Deglycosylation of rLigANI and rLipL32 produced by
P pastoris. To evaluate the post-translational modification of the
rLigANI and rLipL32 proteins produced and secreted by P. pastoris,
the proteins were deglycosylated with PNGase F and Endo H. The
resultant proteins were visualized by (A) Western blotting with
polyclonal anti-LigANI sera and an anti-LipL32 Mab or by (B) SDS-
PAGE stained with Coomassie blue. The proteins were digested with
PNGase F, Endo H or without enzyme (-). E-LigANI (61 kDa) and E-
LipL32 (32 kDa) recombinant proteins were expressed and purified
from E. coli.
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other Leptospira proteins and they do not induce steri-
lizing immunity, reviewed in [26]. Several reports sug-
gest that the most likely explanation for the lack of a
consistent protective effect with recombinant proteins
produced in E. coli is the failure of the proteins to fold
correctly [13,22]. Structural modelling of Lig molecules
predicted that the bacterial immunoglobulin-like (Big)
repeat domains have a highly folded b-immunoglobulin
sandwich structure [27]. E. coli expressed the full-length
LigA at very low levels because of its high toxicity,
which resulted in a 50-fold decrease in viability of cells
[28]. Furthermore, expression of recombinant LigA in
the E. coli pET expression system failed [14].
P. pastoris is an important host organism for the pro-
duction of recombinant proteins [19]. The large-scale
production of recombinant proteins is necessary for
pharmaceutical, biomedical and biotechnological appli-
cations, therefore it is important to develop and to opti-
mize techniques for increased yield of the proteins of
interest. In this work we cloned and expressed a C-
terminal fragment of LigA, LigANI, which includes six
Big repeat domains of the LigA protein, in the methylo-
trophic yeast P. pastoris. In addition, the full-length
LipL32 protein was also expressed as a secreted protein.
Previously we reported the expression of recombinant
LigANI in E. coli with a yield of 6-10 mg/L [13], while
recombinant LipL32 was expressed at 40 mg/L [29]. In
this study we report that large-scale expression in P.
pastoris resulted in yields of over 250 mg/L for both rLi-
gANI and rLipL32, without the need for subsequent
solubilisation and/or re-folding steps. The strain used in
this study, KM71 H, has a deletion in the AOX1 gene,
which is partly replaced by ARG4 from S. cerevisiae and
the phenotype of these strains is MutS (Methanol utili-
zation slow). The use of such strains is advantageous as
they do not require large amounts of methanol in large-
scale cultures [19-21].
Three low-cost purification strategies were evaluated,
namely: i) ammonium sulphate precipitation and
desalting by dialysis, ii) ultrafiltration and iii) lyophili-
sation. The most significant results in terms of yield
were obtained using lyophilisation and ultrafiltration to
purify and/or concentrate the proteins. This is an
important observation as these techniques are applic-
able to large-scale cultures grown in bioreactors on an
industrial scale. During ultrafiltration the columns
used had a cut-off of 30 kDa and our results demon-
strated a decreased yield of the rLipL32 protein, possi-
bly due to the fact that the cut-off is very close to the
molecular weight of the recombinant protein. There
was a significantly lower yield of both rLigANI and
rLipL32 when purified by ammonium sulphate
precipitation.
LigANI and LipL32 were predicted to contain poten-
tial N-glycosylation sites and treatment of the recombi-
nant proteins with the enzymes Endo H and PNGase F
confirmed that post-translational modification had
occurred during production and secretion in P. pastoris,
Figure 4. Deglycosylation removed the N-glycans
attached to asparagine and when analysed by SDS-
PAGE and Western blotting, rLigANI and rLipL32 had
similar molecular weights as the corresponding proteins
expressed in E. coli. N-glycosylation in yeast has a com-
position of MannGlcNAc2 (Man: Mannose; GlcNAc:
N-acetylglucosamine), where n is the number of man-
nose oligosaccharides attached to the structure. This
number has been found to vary in P. pastoris from 3 to
17, depending on the expressed protein [30,31]. The
attachment of a large number of mannose residues,
known as hyperglycosylation, is rarely observed in P.
pastoris, compared to S. cerevisiae which hyperglycosy-
lates the majority of expressed proteins. Glycosylation
can be influenced by some of the bioprocess parameters
used during growth and purification steps [32,33].
Therefore, secreted proteins that are easily recovered
from the growth medium are likely to maintain the
structure of the recombinant protein. This may improve
the protective immune response against leptospirosis
when rLigANI and rLipL32 are used as subunit vaccine
candidates.
Conclusions
We believe that this is the first report of the use of
P. pastoris to express pathogenic Leptospira antigens.
The aim of the study was to evaluate the large-scale
expression of the vaccine candidates LigA and LipL32
proteins in P. pastoris. The rLigANI and rLipL32
LigANI 
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Figure 5 Antigenicity of the various forms of rLigANI and
rLipL32. Antigenicity was evaluated using rabbit anti-Leptospira sera
(A) Lanes: 1 - rLigANI + PNGase F; 2 - rLigANI + Endo H; 3 -
glycosylated rLigANI and (B) Lanes: 4 - rLipL32 + PNGase F; 5 -
rLipL32 + Endo H; 6 - glycosylated rLipL32 or (C) convalescent sera
from leptospirosis patients, Lanes: 1 - glycosylated rLipL32; 2 -
glycosylated rLigANI and (D) 3 - rLipL32 + PNGAse F; 4 - LipL32 +
Endo H; 5 - rLigANI + PNGAse F; 6 - rLigANI + Endo H. E-LigANI (61
kDa) and E-LipL32 (32 kDa) recombinant proteins were expressed
and purified from E. coli.
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proteins described in this study were soluble and the
purification step used simple and inexpensive methods.
Indeed, not only were the proteins expressed at a high
level, but they retained the antigenic characteristics of
native the proteins. Furthermore, glycosylated rLigANI
and rLpiL32 were recognised by the antibodies presents
in the sera of leptospirosis patients and with antibodies
raised against a heterologous Leptospira serovar.
Methods
Bacterial strains and growth conditions
L. interrogans serovar Copenhageni strain Fiocruz L1-
130, originally isolated from a patient with severe leptos-
pirosis [34], was cultivated in Ellinghausen-McCullough-
Johnson-Harris (EMJH) medium supplemented with
Leptospira Enrichment EMJH (Difco, USA) at 30°C. E.
coli strain TOP10 (Invitrogen) was grown in Luria-Ber-
tani (LB) medium (1% tryptone, 0.5% yeast extract, 0.5%
NaCl and 2% agar) at 37°C with the addition of zeocin
to 25 μg/mL. P. pastoris strain KM71 H (MutS, Invitro-
gen) was grown in Yeast extract peptone dextrose
(YPD) medium (1% yeast extract, 2% peptone and 2%
D-glucose) supplemented with 100 μg/mL of zeocin at
28°C.
Cloning ligA and lipL32
We previously identified a C-terminal fragment of LigA,
LigANI, as a vaccine candidate [13]. Primers to amplify
the DNA sequences coding for the LigANI polypeptide
and the full-length lipL32 gene were designed according
the genome sequence of L. interrogans serovar Copenha-
geni strain Fiocruz L1-130 [GenBank: AE016823]. The
primer sequences (EcoRI and KpnI sites are underlined)





PCR products were cloned in-frame into the pPICZaB
vector (Invitrogen, Brazil). The identity of the inserts
was determined by DNA sequencing using the DYE-
namic ET Dye Terminator Cycle Sequencing Kit for
MegaBACE DNA Analysis Systems - MegaBACE 500
(GE Healthcare, Brazil). Recombinant plasmids contain-
ing the LigANI coding sequence, pPIC-LigANI, and
lipL32, pPIC-LipL32, were propagated in E. coli TOP10,
and the plasmids isolated using the Perfectprep Plasmid
Maxi kit (Eppendorf, USA). The plasmids were linear-
ized with restriction enzyme PmeI (New England Bio-
Labs, USA). The linear plasmid DNA was purified by
phenol-chloroform extraction and DNA precipitation.
P. pastoris competent cells were transformed by electro-
poration (25 μF, 200 Ω, 2 kV) with 10 μg of linear plas-
mid DNA.
Screening for expression of recombinant LigANI and
LipL32
Approximately 150 colonies of each plasmid construct
were plated onto Buffered methanol-complex medium
(BMMY: 1% yeast extract, 2% peptone, 1.34% yeast
nitrogen base, 0.00004% biotin, 0.5% methanol, 100 mM
potassium phosphate and 2% agar, pH 6.0). Following
24, 48 and 72 h incubation at 28°C, expression of rLi-
gANI and rLipL32 was induced with 1% methanol and
evaluated after 96 h. Expression of the recombinant pro-
teins was confirmed by colony immunoblotting [35].
Briefly, a nitrocellulose membrane (Hybond ECL, GE
Healthcare) was placed onto the surface of each petri
dish and in direct contact with the colonies for 3 h at
28°C. Any adherent matter was removed from the mem-
brane by washing with PBST (PBS, pH 7.4, 0.05% (v/v)
Tween 20). After blocking (PBST, 5% non-fat dried
milk), the membrane was incubated for 1 h at room
temperature with anti-6×His-peroxidase conjugate
(Sigma-Aldrich, Brazil) at a dilution of 1:8,000 in PBS.
After three washes (5 min each) positive colonies were
detected with 4-chloro-1-naphthol (Sigma-Aldrich).
The presence of the PCR products in the recombinant
plasmids was also confirmed by colony PCR. Crude
genomic DNA extracts were prepared by boiling
selected yeast recombinant clones in water. PCR was
performed as described above, using the crude genomic
DNA extracts as template. PCR products were analysed
by horizontal gel electrophoresis and visualized with
GelRed (Uniscience, Brazil).
Expression of LigANI and LipL32 proteins in P. pastoris
KM71H
A recombinant clone for each construct (rLigANI and
rLipL32), positive for expression and colony PCR, was
selected and inoculated into a 1 L baffled flask contain-
ing 200 mL BMGY broth (differs from BMMY in that
the 1% methanol is replaced by 1% glycerol). The cul-
tures were incubated at 28°C, with shaking (250 rpm),
for approximately 16-18 h until an OD600 of 2 to 6 was
reached. The cells were harvested by centrifugation at
3,000 × g for 5 min and the cell pellet resuspended in
the supernatant equivalent to 1/10 of the original
volume (20 mL). The culture was place in a 100 mL
baffled flask and return to the incubator. Expression was
induced by the addition of methanol to a final concen-
tration of 0.5%. Samples (supernatant and cells) were
collected at the following time points: 0, 24, 48, 72, 96,
120, 144, 168 and 196 h and stored at -80°C. The cell
pellets were suspended in breaking buffer (50 mM
sodium phosphate, 1 mM PMSF, 1 mM EDTA and 5%
glycerol) and an equal volume of acid-washed glass
beads (0.5 mm Ø). The samples were vortexed for 30 s
followed by incubation on ice for 30 s (8 cycles),
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centrifuged at 16,000 × g for 10 min at 4°C and the
cleared supernatant stored at -80°C.
The expression of the recombinant proteins were ana-
lysed by (12%) sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) and visualised by stain-
ing with Coomassie Blue or Western blotting (WB).
Samples were suspended in loading buffer (2% SDS, 500
mM Tris pH 7.6, 1% bromophenol blue, 50% glycerol
and 1% 2-mercaptoethanol) and boiled for 10 min
before separation by SDS-PAGE. For the WB assay the
proteins were electro transferred to a nitrocellulose
membrane (Hybond ECL, GE Healthcare). After block-
ing, PBS, 5% non-fat dried milk, overnight at 4°C and
three washes (5 min per wash) in PBST, the membranes
were incubated for 1 h with anti-LipL32 Mab (1:500 in
PBS) or mouse anti-LigANI polyclonal (1:500 in PBS),
followed by 3 washes (5 min per wash) in PBST. The
rabbit anti-mouse IgG peroxidase conjugate (Sigma-
Aldrich), diluted 1:6,000 in PBS, was added and incu-
bated for 1 h. The membranes were washed 5× in PBST
and the reactions were developed with 4-chloro-1-
naphthol (Sigma-Aldrich).
LigANI and LipL32 were produced in large-scale using
the P. pastoris MutS secretory phenotype, under the
same conditions described above. Briefly, P. pastoris was
grown in BMGY medium (2 L) to an OD600 of 2 to 6,
harvested by centrifugation and suspended in 200 mL
BMMY expression medium (1/10 of the original culture
volume). The expression of the recombinant proteins
was induced for 144 h by the addition of methanol to
0.5%. The supernatant containing the secreted recombi-
nant proteins was cleared by centrifugation, and stored
at -80°C.
Purification and concentration of rLigANI and rLipL32
Three different strategies were used to purify and con-
centrate the secreted recombinant proteins. The first
strategy was based on ammonium sulphate precipitation:
85% ammonium sulphate was added to the culture
supernatant at 4°C, to final concentrations of: 25, 35, 45,
60, 70 and 80%. The precipitated proteins were collected
by centrifugation at 10,000 × g for 15 min at 4°C, sus-
pended in PBS and dialyzed in the same buffer for 48 h.
Microcon YM-30 Amicon Bioseparation filters (Milli-
pore, USA), 30 kDa cut-off, were used to concentrate
the recombinant proteins expressed in the supernatant,
following the manufacturer’s protocol. Alternatively,
proteins were concentrated by lyophilisation (Edwards
Micro Modulyo) over 28 h and suspended in PBS,
resulting in a 10-fold concentration of the initial sample.
The protein concentration in culture supernatants, con-
centrates and purified protein samples were determined
using the BCA Protein Assay Kit (Pierce, USA) with
bovine serum albumin (BSA) as a the standard.
Deglycosylation of rLigANI and rLipL32
Purified rLigANI and rLipL32 (1-20 μg) were incubated
with 1× glycoprotein reaction buffer at 100°C for 10
min to completely denature the glycoproteins. Deglyco-
sylation was carried out at 37°C for 1 h with 5× G5
(Endoglycosidase H) or 10× G7 (N-Glycosidase F) reac-
tion buffer and 1-5 μl of the relevant enzyme (Endogly-
cosidase H or N-Glycosidase F) according to the
manufacturer’s instructions (New England BioLabs).
Antigenicity of rLigANI and rLipL32
The ability of the recombinant proteins to interact spe-
cifically with products of the immune response was
determined by WB using sera collected from leptospiro-
sis patients and hyperimmune sera from infected rabbits.
The use of patient sera for these experiments was
approved by the Internal Review Board of the Gonçalo
Moniz Institute, Fiocruz-BA. A pool of convalescent
sera from severe leptospirosis patients was used at a
dilution of 1:300 and an anti-human IgG peroxidase
conjugate at a 1:2,000 dilution. Rabbit anti-Leptospira
hyperimmune sera, specific to L. interrogans serovar
Canicola strain Tande, was used at a dilution of 1:500
and an anti-rabbit IgG peroxidase conjugate at a 1:3,000
dilution.
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